novo nordisk semaglutide vial faces 'must-win' battle over U.S. Wegovy, Ozempic in 2026 Ozempic: New drugs against obesity

Subgroup analyses indicated that this risk was particularly elevated in individuals receiving high-dose treatment, in studies of long-acting agents, and in overweight/obese populations

Schedule your consultation today and take the next step toward renewed energy and improved well-being

2 REIMAGINE 3 was a 40-week phase 3 trial evaluating the safety and efficacy of CagriSema 2.4 mg/2.4 mg and 1 mg/1 mg once weekly versus dose-matched placebo in 274 adults with T2D as add-on to once-daily basal insulin with or without metformin

John Bacha, specializing in bariatric surgery, offers expert guidance and personal insights to help patients achieve their weight loss goals

It should be handled only by qualified professionals and used strictly for research purposes according to applicable laws, safety standards, and laboratory guidelines